宫颈癌介入治疗术前血清VEGF检测的临床价值  

The Clinical Value of Serum VEGF Levels in Uterine Cervical Cancer Before Interventional Therapy

作　　者：吕益忠[1] 李捷[1] 严建春[1] 祝司龙[1] 张和梅[1] 陈亚梅[1] 

机构地区：[1]江苏大学附属镇江市第四人民医院介入放射科,212001

出　　处：《临床放射学杂志》2012年第9期1320-1323,共4页Journal of Clinical Radiology

摘　　要：目的探讨宫颈癌介入治疗(动脉内灌注化疗)术前血清血管内皮生长因子(VEGF)检测的临床价值及对介入治疗疗效的影响。方法 35例ⅠB-ⅣA期宫颈癌介入治疗术前采用酶联免疫吸附试验(ELISA)测定血清VEGF,比较不同年龄、临床分期、肿瘤分级、病理类型、肿瘤大小、是否淋巴转移的血清VEGF水平差异,分析血清VEGF水平对介入治疗疗效及生存时间的影响;应用多因素Cox风险比例模型分析影响预后的因素。结果血清VEGF在不同肿瘤大小(P=0.001)、病理类型(P=0.026)患者中存在差异;并对介入治疗疗效(P=0.012)及生存时间存在显著影响(log rank P=0.001)。多因素分析显示,临床分期(P=0.019)、血清VEGF水平(P=0.009)、介入治疗疗效(P=0.007)是患者预后的独立影响因素。结论宫颈癌血清VEGF水平对介入治疗疗效及生存时间存在显著影响,具有重要的临床价值。Objective To explore the clinical value of serum VEGF levels before therapy and its impact on the likeli- hood of response to interventional therapy （intraartery chemotherapy）in uterine cervical cancer. Methods Serum VEGF was assessed by Enzyme Linked Immuno Sorbent Assay （ELISA） in 35 patients with cervical cancer （stage IB-IVA） before interventional therapy. Serum VEGF levels correlated with clinical and histopathologie factors including age, stage, tumor grade, histological type, tumor size, position of lymph nodes were compared. The impact of serum VEGF levels on the re- sponse to interventional therapy and overall survival were analyzed. Multivariate survival analysis was performed with the Cox proportional hazards model. Results Serum VEGF levels were significant difference in tumor size （ P = 0. 001 ）, his- topathologic type （P = 0.026 ） , and impact the response to interventional therapy（ P = 0. 012 ） and overall survival （log rank P = 0. 001 ）. Multivariate analysis revealed that stage （ P = 0.019）, serum VEGF levels （ P = 0. 009 ）, the response to interventional therapy（P = 0.007） were independent prognostic factors for overall survival. Conclusion Serum VEGF levels is associated with response to interventional therapy and overall survival in patients with cervical cancer, which have very important value.

关 键 词：血管生成 血管内皮生长因子 宫颈癌 介入治疗 

分 类 号：R737.33[医药卫生—肿瘤]